Breaking News

Financial Report: Covance

January 25, 2013

Late-Stage revenues up 16% in the quarter

Covance
 
4Q Revenues: $562 million (+5%)

4Q Earnings: $33.9 million (+60%)

YTD Revenues: $2.2 billion (+6%)

YTD Earnings: $94.7 million (-28%)

Comments: Late-Stage Development revenues in the quarter grew 16% to $345 million, led by 22% growth in clinical development and 16% growth in central labs, which offset a decline in market access services. For the year Late-Stage Development revenues grew 13% to $1.3 billion. Early Development revenues were down 7% to $217.4 million in the quarter and $869.5 million for the year, due to declines in toxicology, discovery support, and clinical pharmacology, the impact of the sale of environmental services, and the closure of sites in 2012. Restructuring costs were $6.6 million in the quarter and $73.1 million for the year.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016